We have demonstrated that an AURKB/CASP-2 mechanism, regulated by the levels of BID, determines the fate of tumor cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors (Fig. 7A). Here, AURKB is linked to neoplasm.